Ionizable Lipid Nanoparticle Composition for Serum-Free Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle-based delivery systems for nucleic acid drugs face challenges in stability, cell permeability, targeting, storage, distribution, side effects, and cost, necessitating improvements for effective nucleic acid drug delivery.
Innovation Solution
Development of a novel ionizable lipid nanoparticle composition comprising specific compounds, including ionizable lipids, neutral lipids, steroids, and polymeric polylipids, designed for enhanced gene encapsulation and delivery efficacy, even in serum-free environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional lipid nanoparticle formulations are used, then delivery system structure is simple and manufacturing is easier, but gene encapsulation efficiency and delivery efficacy are insufficient
Solution Approach 1:
The patent applies composite materials by formulating lipid nanoparticles with a specific combination of four components: ionizable lipid (30-70 mol%), phospholipid (5-40 mol%), cholesterol (5-30 mol%), and PEG-lipid (0.5-10 mol%). This composite approach enables the nanoparticle to simultaneously achieve high gene encapsulation efficiency, stable structure, and effective cellular delivery, resolving the contradiction between manufacturing simplicity and delivery performance.
Solution Approach 2:
The patent employs parameter changes by optimizing the molar ratios of different lipid components within specific ranges. By adjusting the ionizable lipid content to 30-70 mol% and other components accordingly, the formulation achieves optimal gene encapsulation efficiency and delivery efficacy while maintaining manufacturability through defined compositional parameters.
2Reliability
If lipid nanoparticle composition is optimized for gene delivery, then delivery efficacy improves, but formulation development and manufacturing complexity increase
Solution Approach 1:
The patent establishes specific molar ratio ranges for each lipid component (ionizable lipid: 30-70%, phospholipid: 5-40%, cholesterol: 5-30%, PEG-lipid: 0.5-10%) that reliably produce effective gene delivery. These defined parameter ranges provide a clear formulation guideline that balances delivery efficacy with manufacturability, reducing formulation development complexity while ensuring reliable performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid nanoparticles exhibit excellent gene encapsulation efficiency and delivery efficacy, ensuring effective drug delivery in both in vitro and in vivo systems, including serum-free conditions.
Implementation Method 1
lipid nanoparticles have been used in patisiran, the new siRNA drug first approved by FDA in 2018, as well as mRNA vaccines against COVID-19 approved for emergency use in 2020. Current lipid nanoparticles are generally used in the form in which four constituents, including ionizable lipids, phospholipids (helper lipids), cholesterol (structural maintenance lipids), and PEG-lipids, are mixed in a certain ratio.
Data Source
AI summary
The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same, wherein it has been identified that the lipid nanoparticle composed of the novel ionizable lipid exhibits an excellent rate of gene encapsulation efficiency and of gene delivery efficacy in in vitro/in vivo system and, simultaneously, exhibits an excellent rate of gene delivery efficacy even in serum-free environments, and thus the present invention can be effectively used as a composition for drug delivery.